CN109223751A - Compound L-citrulline plant capsule of high-content active constituent and preparation method thereof - Google Patents
Compound L-citrulline plant capsule of high-content active constituent and preparation method thereof Download PDFInfo
- Publication number
- CN109223751A CN109223751A CN201810918114.2A CN201810918114A CN109223751A CN 109223751 A CN109223751 A CN 109223751A CN 201810918114 A CN201810918114 A CN 201810918114A CN 109223751 A CN109223751 A CN 109223751A
- Authority
- CN
- China
- Prior art keywords
- citrulline
- plant
- capsule
- parts
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- RHGKLRLOHDJJDR-BYPYZUCNSA-N L-citrulline Chemical compound NC(=O)NCCC[C@H]([NH3+])C([O-])=O RHGKLRLOHDJJDR-BYPYZUCNSA-N 0.000 title claims abstract description 169
- 229960002173 citrulline Drugs 0.000 title claims abstract description 84
- 239000002775 capsule Substances 0.000 title claims abstract description 80
- 150000001875 compounds Chemical class 0.000 title claims abstract description 41
- 239000000470 constituent Substances 0.000 title claims abstract description 39
- 238000002360 preparation method Methods 0.000 title claims abstract description 37
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims abstract description 76
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims abstract description 74
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 claims abstract description 47
- 235000014852 L-arginine Nutrition 0.000 claims abstract description 45
- 229930064664 L-arginine Natural products 0.000 claims abstract description 45
- 239000004471 Glycine Substances 0.000 claims abstract description 38
- 239000000377 silicon dioxide Substances 0.000 claims abstract description 37
- 239000000463 material Substances 0.000 claims abstract description 33
- 239000000203 mixture Substances 0.000 claims abstract description 25
- 238000011049 filling Methods 0.000 claims description 15
- 235000001014 amino acid Nutrition 0.000 claims description 13
- 150000001413 amino acids Chemical class 0.000 claims description 13
- 150000003254 radicals Chemical class 0.000 claims description 10
- 239000000126 substance Substances 0.000 claims description 7
- CANRESZKMUPMAE-UHFFFAOYSA-L Zinc lactate Chemical compound [Zn+2].CC(O)C([O-])=O.CC(O)C([O-])=O CANRESZKMUPMAE-UHFFFAOYSA-L 0.000 claims description 6
- 150000007522 mineralic acids Chemical class 0.000 claims description 5
- -1 organic acid gluconic acid zinc salt Chemical class 0.000 claims description 5
- NWONKYPBYAMBJT-UHFFFAOYSA-N zinc;sulfuric acid Chemical compound [Zn+2].OS(O)(=O)=O NWONKYPBYAMBJT-UHFFFAOYSA-N 0.000 claims description 5
- OXAGUGIXGVHDGD-UHFFFAOYSA-H trizinc;2-hydroxypropane-1,2,3-tricarboxylate;dihydrate Chemical compound O.O.[Zn+2].[Zn+2].[Zn+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O OXAGUGIXGVHDGD-UHFFFAOYSA-H 0.000 claims description 4
- 239000004480 active ingredient Substances 0.000 claims description 2
- 239000008104 plant cellulose Substances 0.000 claims description 2
- 241000790917 Dioxys <bee> Species 0.000 claims 2
- 229910003978 SiClx Inorganic materials 0.000 claims 2
- 239000002131 composite material Substances 0.000 claims 1
- 238000005303 weighing Methods 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 abstract description 16
- 238000010521 absorption reaction Methods 0.000 abstract description 5
- 238000005054 agglomeration Methods 0.000 abstract description 2
- 230000002776 aggregation Effects 0.000 abstract description 2
- 238000005516 engineering process Methods 0.000 abstract description 2
- 241000196324 Embryophyta Species 0.000 description 58
- 239000000047 product Substances 0.000 description 14
- 239000011701 zinc Substances 0.000 description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 13
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 11
- 238000000034 method Methods 0.000 description 11
- 230000000694 effects Effects 0.000 description 10
- 229910052725 zinc Inorganic materials 0.000 description 10
- 235000016804 zinc Nutrition 0.000 description 10
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical group O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 9
- 238000012360 testing method Methods 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 238000001514 detection method Methods 0.000 description 5
- 238000011161 development Methods 0.000 description 5
- 230000018109 developmental process Effects 0.000 description 5
- 238000004090 dissolution Methods 0.000 description 5
- 238000002156 mixing Methods 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 4
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 4
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 4
- 206010048259 Zinc deficiency Diseases 0.000 description 4
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 235000019155 vitamin A Nutrition 0.000 description 4
- 239000011719 vitamin A Substances 0.000 description 4
- 229940045997 vitamin a Drugs 0.000 description 4
- HGSXDBRNFBJIMX-UHFFFAOYSA-N 2-aminoacetic acid;zinc Chemical compound [Zn].NCC(O)=O HGSXDBRNFBJIMX-UHFFFAOYSA-N 0.000 description 3
- 208000027418 Wounds and injury Diseases 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000004204 blood vessel Anatomy 0.000 description 3
- 235000009508 confectionery Nutrition 0.000 description 3
- 235000019441 ethanol Nutrition 0.000 description 3
- 230000035558 fertility Effects 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 230000032258 transport Effects 0.000 description 3
- DWNBOPVKNPVNQG-LURJTMIESA-N (2s)-4-hydroxy-2-(propylamino)butanoic acid Chemical compound CCCN[C@H](C(O)=O)CCO DWNBOPVKNPVNQG-LURJTMIESA-N 0.000 description 2
- 239000004475 Arginine Substances 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 241000219112 Cucumis Species 0.000 description 2
- 235000015510 Cucumis melo subsp melo Nutrition 0.000 description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2
- 239000001828 Gelatine Substances 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 206010052428 Wound Diseases 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 150000001370 alpha-amino acid derivatives Chemical class 0.000 description 2
- 235000008206 alpha-amino acids Nutrition 0.000 description 2
- 229910021529 ammonia Inorganic materials 0.000 description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
- 235000009697 arginine Nutrition 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 210000000748 cardiovascular system Anatomy 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000002425 crystallisation Methods 0.000 description 2
- 230000008025 crystallization Effects 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 125000000267 glycino group Chemical group [H]N([*])C([H])([H])C(=O)O[H] 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 238000007689 inspection Methods 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 230000035790 physiological processes and functions Effects 0.000 description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 230000005313 thymus development Effects 0.000 description 2
- HIXDQWDOVZUNNA-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-hydroxy-7-methoxychromen-4-one Chemical compound C=1C(OC)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=C(OC)C(OC)=C1 HIXDQWDOVZUNNA-UHFFFAOYSA-N 0.000 description 1
- 244000241235 Citrullus lanatus Species 0.000 description 1
- 235000012828 Citrullus lanatus var citroides Nutrition 0.000 description 1
- 240000004307 Citrus medica Species 0.000 description 1
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 206010013883 Dwarfism Diseases 0.000 description 1
- 108010001515 Galectin 4 Proteins 0.000 description 1
- 102100039556 Galectin-4 Human genes 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- 206010057190 Respiratory tract infections Diseases 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- FHCZILHPOKONMM-RGMNGODLSA-N [Zn].C(CC)N[C@@H](CCO)C(=O)O Chemical compound [Zn].C(CC)N[C@@H](CCO)C(=O)O FHCZILHPOKONMM-RGMNGODLSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 238000005034 decoration Methods 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 239000010432 diamond Substances 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000011978 dissolution method Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000000174 gluconic acid Substances 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000003914 insulin secretion Effects 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 230000007721 medicinal effect Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 230000009965 odorless effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 238000011020 pilot scale process Methods 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 229940069328 povidone Drugs 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 230000005659 seminal clot liquefaction Effects 0.000 description 1
- 230000014860 sensory perception of taste Effects 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 238000007711 solidification Methods 0.000 description 1
- 230000008023 solidification Effects 0.000 description 1
- 230000008010 sperm capacitation Effects 0.000 description 1
- 230000021595 spermatogenesis Effects 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000001839 systemic circulation Effects 0.000 description 1
- 235000012976 tarts Nutrition 0.000 description 1
- 230000009967 tasteless effect Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- WGIWBXUNRXCYRA-UHFFFAOYSA-H trizinc;2-hydroxypropane-1,2,3-tricarboxylate Chemical compound [Zn+2].[Zn+2].[Zn+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O WGIWBXUNRXCYRA-UHFFFAOYSA-H 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 150000003751 zinc Chemical class 0.000 description 1
- 235000006076 zinc citrate Nutrition 0.000 description 1
- 239000011746 zinc citrate Substances 0.000 description 1
- 229940068475 zinc citrate Drugs 0.000 description 1
- 229940071566 zinc glycinate Drugs 0.000 description 1
- 229940050168 zinc lactate Drugs 0.000 description 1
- 235000000193 zinc lactate Nutrition 0.000 description 1
- 239000011576 zinc lactate Substances 0.000 description 1
- NWONKYPBYAMBJT-UHFFFAOYSA-L zinc sulfate Chemical compound [Zn+2].[O-]S([O-])(=O)=O NWONKYPBYAMBJT-UHFFFAOYSA-L 0.000 description 1
- 229960001763 zinc sulfate Drugs 0.000 description 1
- 229910000368 zinc sulfate Inorganic materials 0.000 description 1
- UOXSXMSTSYWNMH-UHFFFAOYSA-L zinc;2-aminoacetate Chemical compound [Zn+2].NCC([O-])=O.NCC([O-])=O UOXSXMSTSYWNMH-UHFFFAOYSA-L 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4816—Wall or shell material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/485—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Diabetes (AREA)
- Inorganic Chemistry (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Gynecology & Obstetrics (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pregnancy & Childbirth (AREA)
- Emergency Medicine (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Immunology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
The present invention relates to compound L-citrulline plant capsules of a kind of high-content active constituent and preparation method thereof, it is characterized by: based on parts by weight, supplementary material components composition includes 50-60 parts of L-arginine, 20-30 parts of L-citrulline, 0.5-2 parts of glycine zine, 0-0.5 parts of silica, 14-18 parts of plant hollow capsule.A kind of compound L-citrulline plant capsule of high-content active constituent of the present invention and preparation method thereof production technology is easy, and by controlling material size, order by merging reaches purpose easy to industrialized production, and products obtained therefrom quality is stablized, and industrialized production is easy to;Phenomena such as each storeroom has good compatibility, and products obtained therefrom can keep quality to stablize in a long time, will not send out the moisture absorption, agglomeration, meets the needs transport, store, using.
Description
Technical field
The present invention relates to compound L-citrulline plant capsules of a kind of high-content active constituent and preparation method thereof.
Background technique
1, title and physicochemical property
[L-citrulline] English name: L-Citrulline, CAS No.:372-75-8, molecular formula: C6H13N3O3, molecule
Amount: 175.19, structural formula:
Appearance characteristics: white crystalline body or crystalline powder have tart flavour, are slightly soluble in water, do not dissolve in ethyl alcohol
And ether;20D+24.5~+26.8 ° of [α];PH 5.0~7.0.
[L-arginine] English name: L (+)-Arginine, CAS No.:74-79-3, molecular formula: C6H14N4O2, molecular weight:
174.20 structural formula:Appearance characteristics: white diamond crystallization, odorless, bitter;It is soluble easily in water
(solubility is 83g/L in 0 DEG C of water, and solubility is 400g/L in 50 DEG C of water), it is atomic to be dissolved in ethyl alcohol, do not dissolve in ether;pI6.0;
It is heated to losing two molecular crystalline water at 105 DEG C, 230 DEG C of whens darken, and decomposition point is 244 DEG C;Specific rotatory power [α] 20D+
12.5 ° (0.5-2.0mg/ml, H2O), 20D+27.3 ° of [α] (0.5-2.0mg/ml, 6mol/L HCl);Aqueous solution is in 205nm
There is absorption maximum at place.
[glycine zine] Chinese name: glycine zine (an anhydrous or water), English name: Zinc glycinate, molecular formula: Zn
(C2H4NO2)2Or Zn (C2H4NO2)2·H2O, molecular weight: 213.51 or 231.51, structural formula: (anhydrous)Appearance characteristics: white crystals, particulate powder, it is tasteless;It is slightly soluble in water, does not dissolve in ethyl alcohol, easily
It is dissolved in slightly acidic water;Middle stability is good.Theoretical Zn content containing the crystallization water is 28.24%, and anhydrous theory Zn content is
30.62%.
2, physiological action and effect
L-citrulline is gained the name from the watermelon for extracting citrulling first, it is a kind of alpha amino acid, to human body
Speech, citrulling is a kind of nonprotein amino acid, is not involved in the synthesis of protein.Past often thinks that citrulling does not have clinical meaning
Justice, but recent studies have found that citrulling and a variety of diseases in relation to its judge index that can be used as injury of gastrointestinal tract;Arginine lacks
Effective supplement drug of patient;The evidence of septicopyemia change of illness state;And it in the forming process of citrulling, is led as antigen
The generation of patient's rheumatoid arthritis is caused, rheumatoid arthritis can sentence in early days by detection citrulling associated antibodies
It is disconnected;Citrulling has certain diagnosis and therapeutic effect also for certain diseases;In addition, citrulling is answered in terms of safeguarding human health
With extensive.
L-arginine is a kind of amino acid, is also 20 kinds of universal one of natural amino acid.In mammals, arginine
It is classified as the half necessary or necessary amino acid of conditionity, depending on stage of development and health status.L-arginine is a kind of α
Amino acid, be primarily involved in urea metabolism and excretion and DNA synthesis and protein production.It is nitric oxide
(NO) a important as precursors, plays a role in blood vessel dilatation.For adult, though be not required amino acid has in vivo
Important function, male sexual disfunction can be improved, expansion blood vessel increases blood flow, improves systemic circulation, and can prevent height
Blood pressure, respiratory tract infection and increase insulin secretion.
Glycine zine is a kind of amino-acid zinc, and zinc plays a significant role human body, shows themselves in that the growth of 1, promotion human body
Development: if the children and adolescents zinc-deficiency in growth and development stage, will lead to depauperation.When lacking serious, it will cause "
Nanism " and intellectual development are bad;2, maintain human normal appetite: zinc-deficiency will lead to sense of taste decline, anorexia, partial eclipse occurs even
Different food;3, enhance human immunity: Zn-ef ficiency is the nutrient of immune organ thymus development, and only zinc amount abundance could be protected effectively
Thymus development is demonstrate,proved, normal differentiation T lymphocyte promotes cellular immune function;4, promote the healing of wound and wound: zinc supplementation agent
It is applied to clinical be exactly to be used to treat skin disease earliest;5, metabolism and the normal vision of vitamin A: zinc clinically table are influenced
Now to be beneficial to eyes, exactly because zinc plays the role of promoting vitamin A absorption.The absorption of vitamin A be unable to do without zinc.Vitamin
It is stored in liver when A is flat, when human body needs, vitamin A is transported in blood, this process is " dynamic to complete by zinc
Member " work: 6, maintain the normal spermatogenesis of male: Zn-ef ficiency is largely present in male testical, participates in the entire of sperm
It generates, mature and capacitation process.Once male's zinc-deficiency will lead to sperm quantity reduction, vigor decline, semen liquefaction not
Good, zinc-deficiency, which also results in teenager, does not have secondary sex characters to occur, be unable to normal reproductive development.The sweet ammonia of carrier as Zn-ef ficiency
Acid belongs to one kind of gal4 amino acid, has benefiting action, superior now widely used zinc sulfate, gluconic acid to human body
Zinc, zinc lactate and zinc citrate etc..
There is silica good preparation to help stream effect, and dosage is few in preparation manufacture, reduces volumes of formulation weight, subtracts simultaneously
The dose of few unnecessary substance of human body;Plant hollow capsule derives from plant rather than source compared with traditional gelatine capsule
In animal tissue, advantage is extremely obvious, and clean safety, supplementary material compatibility is good, and product stability is higher.
Although L-citrulline and L-arginine can make human body produce a nitrogen oxides, such as two kinds of amino acid are combined and are made
With under the synergistic effect of L-citrulline, human body being allowed to generate an a large amount of oxygen with L-arginine for nitric oxide production basic substance
Change nitrogen;It is remarkably reinforced compared to single use L-arginine effect;It adds glycine zine and Zn-ef ficiency is provided, meeting physiological need
Zn-ef ficiency needed for sperm manufactures is replenished in time simultaneously, its solidification group is combined into a novel perfect medicinal properties field of food
The apparent complex of effect with antioxidation, the intracorporal Free Radical of removing people, the muscle strength for enhancing human body and resists
Fatigue effect, promotes the effect of sperm manufacture level at expansion blood vessel function.Silica is selected to cook retention agent, plant in product manufacturing
Object Capsules do filling softgel shell, produce compound L-citrulline plant capsule, meet the need for producing, transport, storing and using
It wants, provides service for the healthy living of people, meet adult male and changing and improving physical efficiency, improving function of immune system, balance
Blood glucose level, maintenance cardiovascular system, the health care demand for improving fecundity.
It there are no the report of the compound preparation and its preparation process that close mentioned component composition at present.
Summary of the invention
Have effects that the high-content for meeting adult male improvement physiological function is living the purpose of the present invention is to provide a kind of
The compound L-citrulline plant capsule and preparation method thereof of property ingredient.
A kind of compound L-citrulline plant capsule combination preparation of high-content active constituent of the present invention, it is characterised in that: with
Parts by weight meter, supplementary material components composition include 50-60 parts of L-arginine, 20-30 parts of L-citrulline, glycine zine
0.5-2 parts, 0-0.5 parts of silica, 14-18 parts of plant hollow capsule.
Preferably, based on parts by weight, raw material components include 52-58 parts of L-arginine, 24-28 parts of L-citrulline, sweet
0.7-1.5 parts of propylhomoserin zinc, 0.1-0.3 parts of silica, 15-17 parts of plant hollow capsule.
A kind of compound L-citrulline plant capsule of high-content active constituent of the present invention, it is characterised in that the active constituent
Containing also containing only L-arginine, L-citrulline and three kinds of glycine zine, fix prescription is L-arginine based on parts by weight
50-60 parts, 20-30 parts of L-citrulline, glycine zine 0.5-2.
A kind of compound L-citrulline plant capsule of high-content active constituent of the present invention, it is characterised in that it is described it is nonactive at
It is divided to and is no more than two kinds, silica, plant hollow capsule, and the parts by weight shared by entire auxiliary material component composition are total does not surpass
Cross 20%.
A kind of compound L-citrulline plant capsule of high-content active constituent of the present invention, it is characterised in that the L- melon
Propylhomoserin is the levo form of citrulling, and is free radical;L-arginine is arginic levo form, and is free radical;Glycine zine
For Zn-ef ficiency carrier, it is amino acid, excludes inorganic acid sulfuric acid zinc salt, organic acid gluconic acid zinc salt, lactic acid zinc salt and citron
Sour zinc salt.
A kind of compound L-citrulline plant capsule of high-content active constituent of the present invention, it is characterised in that the silica
It is partial size less than the anti-antiplastering aid of 80 purposes;Plant hollow capsule, main chemical compositions be plant cellulose, model 0.
A kind of compound L-citrulline plant capsule of high-content active constituent of the present invention, preparation method are as follows:
1) feeding is sieved: weigh supplementary material by recipe quantity, L-arginine and L-citrulline crossed into 40 meshes, glycine zine with
Silica crosses 80 meshes, spare;
2) mix: first will L-arginine and L-citrulline it is just mixed, glycine zine and silica are just mixed, then by glycine zine
Just L-arginine is added with L-citrulline just mixed material in mixed material with silica, is uniformly mixed, mixing before must filling
Material;
3) it fills: taking plant hollow capsule, on capsule filling machine, above-mentioned satisfactory mixed material is directly filled
In plant capsule, the compound L-citrulline plant capsule combination preparation of this product high-content active constituent is obtained.
What above-mentioned technique referred to pulverize and sieve, mix, filling and etc. can carry out in GMP environmental condition, without being important to
It asks.
A kind of compound L-citrulline plant capsule of high-content active constituent of the present invention and preparation method thereof, preparation process
Full powder filling technique technique is taken, key control parameter is each material size of control, as L-arginine crosses 40 mesh, L-citrulline
40 mesh are crossed, glycine zine crosses 80 mesh, and silica crosses 80 mesh;Crucial order by merging, it is first that L-arginine and L-citrulline is just mixed,
Glycine zine and silica are just mixed, then will be at the beginning of the first mixed material of glycine zine and silica and L-arginine and L-citrulline
Mixed material mixing, final mixture are not only uniformly mixed, and mobility is also good, can meet full powder and directly be filled in No. 0 plant
Capsules, entire preparation process not only ensure that product can be cut products obtained therefrom quality and be stablized with industrialized production.
The invention has the advantages that production technology is easy, by controlling material size, order by merging reaches and is easy to industrialize
Purpose is produced, and products obtained therefrom quality is stablized, and industrialized production is easy to;Each storeroom has good compatibility, and gained produces
Phenomena such as product can keep quality to stablize in a long time, will not send out the moisture absorption, agglomeration, meets the need transport, store, using
It wants.A kind of compound L-citrulline plant capsule of high-content active constituent of the present invention contains there are three types of active constituent, reasonable recipe, has
There is synergistic effect;Two kinds of non-active ingredients, proportion is few in component, this component selection silica as glidant, although
Dosage is few but is able to satisfy production needs;Softgel shell select plant capsule, exclude gelatine capsule, not only safety but also meet production requirement.It should
There is good compatibility between each component of the compound L-citrulline plant capsule of high-content active constituent, while there is industrialization
The convenience of production, the stability of product, carrying convenience and take adaptability.The compound L- melon of the high-content active constituent
Propylhomoserin plant capsule preparation unit as a whole, is highly suitable for adult male, and meeting adult male improves physiological function
The effect of, it shows and changes and improves physical efficiency, improves horizontal function of immune system, balance blood sugar, maintenance cardiovascular system, promotion essence
Sub- manufacture level improves fecundity, often takes in the compound L-citrulline plant capsule of high-content active constituent of the invention,
Fatigue can not only be effectively relieved, improve immunity, more can help to improve sperm quality, improve fecundity.
Specific embodiment
Below with reference to embodiment, the present invention is described in further detail, but the embodiment invented is without being limited thereto.
Embodiment 1: a kind of compound L-citrulline plant capsule combination preparation of high-content active constituent, with parts by weight
Meter, supplementary material components composition includes 50 parts of L-arginine, 20 parts of L-citrulline, 0.5 part of glycine zine, silica 0.1
Part, 14 parts of plant hollow capsule.
The L-citrulline is the levo form of citrulling, and is free radical;L-arginine is arginic levo form, and
For free radical;Glycine zine be Zn-ef ficiency carrier, be amino acid, exclude inorganic acid sulfuric acid zinc salt, organic acid gluconic acid zinc salt,
Lactic acid zinc salt and citric acid zinc salt.
Silica is partial size less than the anti-antiplastering aid of 80 purposes;Plant hollow capsule, main chemical compositions are that plant is fine
Dimension element, model 0.
A kind of compound L-citrulline plant capsule of high-content active constituent, preparation method are as follows:
1) feeding is sieved: weigh supplementary material by recipe quantity, L-arginine and L-citrulline crossed into 40 meshes, glycine zine with
Silica crosses 80 meshes, spare;
2) mix: first will L-arginine and L-citrulline it is just mixed, glycine zine and silica are just mixed, then by glycine zine
Just L-arginine is added with L-citrulline just mixed material in mixed material with silica, is uniformly mixed, mixing before must filling
Material;
3) it loads: taking plant hollow capsule, on capsule filling machine, above-mentioned satisfactory mixed material is directly filled
In plant capsule, the compound L-citrulline plant capsule combination preparation of this product high-content active constituent is obtained.
Embodiment 2: embodiment 1: a kind of compound L-citrulline plant capsule combination preparation of high-content active constituent, with weight
Number meter is measured, supplementary material components composition includes 60 parts of L-arginine, 30 parts of L-citrulline, 2 parts of glycine zine, silica
0.5 part, 18 parts of plant hollow capsule.
The L-citrulline is the levo form of citrulling, and is free radical;L-arginine is arginic levo form, and
For free radical;Glycine zine be Zn-ef ficiency carrier, be amino acid, exclude inorganic acid sulfuric acid zinc salt, organic acid gluconic acid zinc salt,
Lactic acid zinc salt and citric acid zinc salt.
Silica is partial size less than the anti-antiplastering aid of 80 purposes;Plant hollow capsule, main chemical compositions are that plant is fine
Dimension element, model 0.
A kind of compound L-citrulline plant capsule of high-content active constituent, preparation method are as follows:
2) feeding is sieved: weigh supplementary material by recipe quantity, L-arginine and L-citrulline crossed into 40 meshes, glycine zine with
Silica crosses 80 meshes, spare;
2) mix: first will L-arginine and L-citrulline it is just mixed, glycine zine and silica are just mixed, then by glycine zine
Just L-arginine is added with L-citrulline just mixed material in mixed material with silica, is uniformly mixed, mixing before must filling
Material;
3) it loads: taking plant hollow capsule, on capsule filling machine, above-mentioned satisfactory mixed material is directly filled
In plant capsule, the compound L-citrulline plant capsule combination preparation of this product high-content active constituent is obtained.
Embodiment 3: embodiment 1: a kind of compound L-citrulline plant capsule combination preparation of high-content active constituent, with weight
Number meter is measured, supplementary material components composition includes 56 parts of L-arginine, 24 parts of L-citrulline, 1 part of glycine zine, silica
0.2 part, 16 parts of plant hollow capsule.
The L-citrulline is the levo form of citrulling, and is free radical;L-arginine is arginic levo form, and
For free radical;Glycine zine be Zn-ef ficiency carrier, be amino acid, exclude inorganic acid sulfuric acid zinc salt, organic acid gluconic acid zinc salt,
Lactic acid zinc salt and citric acid zinc salt.
Silica is partial size less than the anti-antiplastering aid of 80 purposes;Plant hollow capsule, main chemical compositions are that plant is fine
Dimension element, model 0.
A kind of compound L-citrulline plant capsule of high-content active constituent, preparation method are as follows:
3) feeding is sieved: weigh supplementary material by recipe quantity, L-arginine and L-citrulline crossed into 40 meshes, glycine zine with
Silica crosses 80 meshes, spare;
2) mix: first will L-arginine and L-citrulline it is just mixed, glycine zine and silica are just mixed, then by glycine zine
Just L-arginine is added with L-citrulline just mixed material in mixed material with silica, is uniformly mixed, mixing before must filling
Material;
3) it loads: taking plant hollow capsule, on capsule filling machine, above-mentioned satisfactory mixed material is directly filled
In plant capsule, the compound L-citrulline plant capsule combination preparation of this product high-content active constituent is obtained.
Embodiment 4: the compound L-citrulline plant capsule combination preparation of high-content active constituent
[composition]
[preparation process]
The present embodiment 4 selects carrier of the general anhydrous glycine zinc as Zn-ef ficiency, carries out experimental study, and recipe quantity is pressed
Pilot scale recipe quantity feeds intake, and technical process is as follows:
1, each supplementary material (without Capsules shell) is taken, is pulverized and sieved, L-arginine and L-citrulline cross 40 meshes, anhydrous
Glycine zine and silica cross 80 meshes;
2, L-arginine, L-citrulline, anhydrous glycine zinc, silica are weighed by recipe quantity;
3, first will L-arginine and L-citrulline it is just mixed, anhydrous glycine zinc and silica are just mixed, then by anhydrous sweet ammonia
Just L-arginine is added with L-citrulline just mixed material in mixed material for sour zinc and silica, is uniformly mixed, before obtaining filling
Mixed material;
4, intermediate detects, and above-mentioned material is carried out content and water content detection, spare after meeting the requirements;
5, No. 0 type plant hollow capsule is taken, on capsule filling machine, above-mentioned satisfactory mixed material is directly filled
In plant capsule, this product compound L-citrulline plant capsule combination preparation, every weight 470mg or so are obtained;
6, it packs, takes coloured plastics material canopy, above-mentioned capsule is packed on packing machine, every bottle is not less than 60, then pastes
Upper label mixes specification, last carton package.
7, full inspection is sampled full inspection to above-mentioned packaged compound L-citrulline plant capsule combination preparation product, symbol
Standardization is let pass.
Embodiment 5: the compound L-citrulline plant capsule combination preparation of high-content active constituent
[composition]
[Dissolution Rate Testing]
Embodiment 4 is measured by the first method (turning blue laws) in 2015 editions two annex XC dissolution methods of Chinese Pharmacopoeia
With the dissolution rate of the compound L-arginine plant capsule combination preparation sample of 5 high-content active constituent of embodiment.Condition: dissolution is situated between
Matter: purified water 900ml;
Revolving speed: 100 turns;
Temperature: 37 DEG C;
Sample time: 15 minutes;
Detection: using the amount of dissolution of important activity ingredient L-citrulline as Testing index.
As a result: 15 minutes the amount of dissolutions of L-citrulline are not less than 80%.
[content detection]
Method: high performance liquid chromatography, using the content of important activity ingredient L-citrulline as Testing index.Its efficient liquid
Phase chromatographic condition: ODS C18 (250mm × 4.6mm, 5 μm) chromatographic column, using 0.03mmol/L phosphoric acid as mobile phase, flow velocity
0.7mL/min, 30 DEG C of column temperature, Detection wavelength 202nm.
As a result: the content of L-citrulline is the 90%-110% of labelled amount.
Stability study (accelerated test)
According to by 2015 editions two annex XC stability experiment requirements of Chinese Pharmacopoeia, embodiment 4,5 preparations are carried out
Accelerated test (40 DEG C ± 2 DEG C, RH75% ± 5%), accelerated test result is as follows within 6 months:
Accelerated test investigates result
[note]: embodiment 4 and embodiment 5 are all made of coloured expected bottle packaging sample;
The above results show that addition povidone makees 4 preparation of embodiment of stabilizer, with the effervescent formulation for not adding stabilizer
It compares, produces gas phenomenon and be obviously reduced, the stability of Apparent character is significantly improved.
The above is a preferred embodiment of the present invention, has simple process, easy to industrialized production, product quality is excellent
Good, storage stability is good, can satisfy production, transport, storage, the actual needs used.It needs to particularly point out, for this skill
For the those of ordinary skill in art field, without departing from the principle of the present invention, several retouchings can also be made, these profits
Decorations are also considered as protection scope of the present invention.
Claims (6)
1. a kind of compound L-citrulline plant capsule combination preparation of high-content active constituent, it is characterised in that: with parts by weight
Meter, supplementary material components composition includes 50-60 parts of L-arginine, 20-30 parts of L-citrulline, 0.5-2 parts of glycine zine, dioxy
0-0.5 parts of SiClx, 14-18 parts of plant hollow capsule.
2. a kind of compound L-citrulline plant capsule of high-content active constituent according to claim 1, it is characterised in that
The active constituent, which contains, also contains only L-arginine, L-citrulline and three kinds of glycine zine, fixes prescription with parts by weight
It is calculated as, 50-60 parts of L-arginine, 20-30 parts of L-citrulline, glycine zine 0.5-2.
3. a kind of compound L-citrulline plant capsule of high-content active constituent according to claim l, it is characterised in that
The non-active ingredient is no more than two kinds, silica, plant hollow capsule, and the weight shared by entire auxiliary material component composition
Number is total to be no more than 20%.
4. a kind of compound L-citrulline plant capsule of high-content active constituent according to claim 2, it is characterised in that
The L-citrulline is the levo form of citrulling, and is free radical;L-arginine is arginic levo form, and for freely
Base;Glycine zine is Zn-ef ficiency carrier, is amino acid, excludes inorganic acid sulfuric acid zinc salt, organic acid gluconic acid zinc salt, zinc lactate
Salt and citric acid zinc salt.
5. a kind of compound L-citrulline plant capsule of high-content active constituent according to claim 3, it is characterised in that
The silica is partial size less than the anti-antiplastering aid of 80 purposes;Plant hollow capsule, main chemical compositions are plant cellulose,
Model 0.
6. a kind of compound L-citrulline plant capsule of high-content active constituent according to claim 1, preparation method
Are as follows:
1) feeding is sieved: weighing supplementary material by recipe quantity, L-arginine and L-citrulline are crossed 40 meshes, glycine zine and dioxy
SiClx crosses 80 meshes, spare;
2) mix: first will L-arginine and L-citrulline it is just mixed, glycine zine and silica are just mixed, then by glycine zine and two
Just L-arginine is added with L-citrulline just mixed material in mixed material to silica, is uniformly mixed, mixed material before must filling;
3) it loads: taking plant hollow capsule, on capsule filling machine, above-mentioned satisfactory mixed material is directly filled in plant
In composite capsule, the compound L-citrulline plant capsule combination preparation of this product high-content active constituent is obtained.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810918114.2A CN109223751A (en) | 2018-08-13 | 2018-08-13 | Compound L-citrulline plant capsule of high-content active constituent and preparation method thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810918114.2A CN109223751A (en) | 2018-08-13 | 2018-08-13 | Compound L-citrulline plant capsule of high-content active constituent and preparation method thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
CN109223751A true CN109223751A (en) | 2019-01-18 |
Family
ID=65070413
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201810918114.2A Pending CN109223751A (en) | 2018-08-13 | 2018-08-13 | Compound L-citrulline plant capsule of high-content active constituent and preparation method thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN109223751A (en) |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9572848B1 (en) * | 2014-03-26 | 2017-02-21 | Aemes Research L.L.L.P. | Composition of matter for sexual dysfunction |
-
2018
- 2018-08-13 CN CN201810918114.2A patent/CN109223751A/en active Pending
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9572848B1 (en) * | 2014-03-26 | 2017-02-21 | Aemes Research L.L.L.P. | Composition of matter for sexual dysfunction |
Non-Patent Citations (1)
Title |
---|
美健品联盟: "美国GNC健安喜L-精氨酸+L-瓜氨酸(加强型)成人男性保养品", 《HTTP://BBS.MEIJIANPIN.COM/CRNXBJP/P6923/》 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN104381586A (en) | Soybean peptide protein powder with scientific and reasonable proportion and preparation method of soybean peptide protein powder | |
CN110179017A (en) | A kind of preparation method of the rose collagen peptide beverage with effects of beautification and nourishing face | |
CN105792818A (en) | Composition useful for promoting female fertility | |
CN101264088A (en) | Antibiotics composition with stable content and rapid solubility | |
CN110558388A (en) | Formula of yak milk powder for old people and preparation method thereof | |
CN104323283A (en) | Coenzyme Q10-containing nutritional composition as well as preparation method and application of coenzyme Q10-containing nutritional composition | |
CN109619308A (en) | It is a kind of for improving cat immunity prevent cat nose nutrition paste formulation and preparation method thereof | |
CN102028230B (en) | Health care product auxiliary material and application thereof | |
CN109223751A (en) | Compound L-citrulline plant capsule of high-content active constituent and preparation method thereof | |
CN103478718B (en) | Improve functional food of glutathione concentration in human body and preparation method thereof | |
CN101822822A (en) | Drug composition of pramlintide and preparation method thereof | |
CN103655574A (en) | Compound ferrous succinate and folic acid composition | |
CN1247199C (en) | Nutrition supplement agent | |
CN104224745A (en) | A capsule shell of a traditional Chinese medicine soft capsule and a preparing method thereof | |
CN107048129A (en) | A kind of antifatigue crocodile polypeptide beverage | |
US10245278B2 (en) | Liquid or semi-liquid pharmaceutical, dietary or food composition free of bitterness containing an arginine salt | |
CN102499366A (en) | Health-care food for adjusting blood fat and preventing fatigue | |
WO2019119445A1 (en) | Nadh compound, and formulation and application thereof | |
US20220387482A1 (en) | Performance enhancement delivery system | |
CN104548107B (en) | A kind of slow controlled release pharmaceutic adjuvant for improving main ingredient stability | |
CN103719990B (en) | A kind of functional beverage containing spirulina and stripped tuna bone extract | |
CN100364969C (en) | Water soluble vitamins D2 preparation method | |
US11617714B2 (en) | Sublingual therapeutic solutions and methods | |
CN103181568A (en) | Eucommia seed oil vitamin compound soft capsule preparation and preparation method thereof | |
CN102318832A (en) | Nutrition agent for improving body anti-anoxia capability |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20190118 |